# Colgate Palmolive Co.

**CL**

NYSE; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0000021665

**A**

**strongest fifth of 329 graded peers in the pooled industrial gr...**

rank 40 of 329; percentile 13.7; sampling error 2.7 points; lower is stronger

A B C D E

**A, the bull**



| Scoreboard | |
|---|---|
| **Profitability** | A<br>percentile 9.8 |
| **Solvency** | C<br>percentile 53.4 |
| **Growth and financing** | C<br>percentile 47.7 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $16.3B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 12 of 14 |
| **Graded from** | filings received through Feb 23, 2026<br>265 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026 |
| **Last close** | $99.68<br>2026-11-13; market equity $79.2B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 23, 2026*

Colgate-Palmolive Company (together with its subsidiaries, "we," "us," "our," the "Company" or "Colgate-Palmolive") is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. To achieve our business and financial objectives and deliver peer-leading performance and total shareholder return, we are focused on driving organic sales growth; delivering consistent, compounded earnings per share growth; achieving operational efficiencies; and driving growth in free cash flow along with the efficient use of our balance sheet.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 9.8** | | | | | | |
| Gross profitability | 75.0% | 21.4% | | 1.7 | 356 | 2025-12-31 |
| Return on invested capital | 38.4% | 9.5% | | 4.1 | 124 | 2025-12-31 |
| Accruals ratio | (12.8%) | (4.2%) | | 15.1 | 393 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | 1.3 pts | 2.2 pts | | 18.5 | 299 | 2025-12-31 |
| **Solvency, sleeve percentile 53.4** | | | | | | |
| Twelve-month failure probability | not computable | 0.05% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | 6.21 | 3.42 | | 20.1 | 295 | 2025-12-31 |
| Net debt to EBITDA | 1.66x | 1.86x | | 44.6 | 149 | 2025-12-31 |
| Interest coverage | not computable | 4.16x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 0.83x | 2.20x | | 95.4 | 418 | 2025-12-31 |
| **Growth and financing, sleeve percentile 47.7** | | | | | | |
| Revenue growth, three-year compound | 4.3% | 1.2% | | 35.2 | 348 | 2025-12-31 |
| Free cash flow growth, three-year compound | 25.0% | 12.5% | | 31.8 | 180 | 2025-12-31 |
| Reinvestment rate | (31.4%) | 19.3% | | 80.8 | 168 | 2025-12-31 |
| Asset growth, three years | 1.3% | 2.8% | | 60.2 | 363 | 2025-12-31 |
| Net share issuance, one year | (1.2%) | 0.0% | | 30.3 | 315 | 2026-01-31 |

## Among 329 peers

*chemicals; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 35 | Axil Brands, Inc. (AXIL) | 11.9 | A | fortress balance sheet |
| 36 | Lincoln Electric Holdings Inc. (LECO) | 12.3 | A | |
| 37 | National Presto Industries Inc. (NPK) | 12.6 | A | |
| 38 | Compx International Inc. (CIX) | 13.0 | A | fortress balance sheet |
| 39 | Weatherford International Corp. (WFRD) | 13.4 | A | |
| 40 | Colgate Palmolive Co. (CL) | 13.7 | A | |
| 41 | Acme United Corp. (ACU) | 13.8 | A | |
| 42 | Newmarket Corp. (NEU) | 14.0 | A | |
| 43 | Park Aerospace Corp. (PKE) | 14.2 | A | late filer, fortress balance sheet |
| 44 | Innospec Inc. (IOSP) | 14.3 | A | fortress balance sheet |
| 45 | Kadant Inc. (KAI) | 14.6 | A | |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 12.8% | 10.9% | 52 |
| Distance from 52-week high | 0.0% | (24.4%) | 98 |
| EBIT to enterprise value | 3.9% | 3.8% | 52 |
| Free cash flow yield | 4.6% | 3.3% | 64 |
| Book value to price | 0.00 | 0.39 | 5 |
| Sales to price | 0.26 | 0.55 | 21 |
| Composite equity issuance, five years | (19.5%) | (10.2%) | 24 |
| Relative strength against the sector, log excess return | (0.02) | 0.00 | 46 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 6 of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $1.5B |
| Operating cash flow, four quarters | $4.4B |
| Months of runway | not finite |
| Days since last periodic filing | 16 (10-Q received Oct 30, 2026) |
| Median daily dollar volume, 63 sessions | $428.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $12.3B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 2 | assets | us-gaap:Assets | $16.3B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $3.3B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $3.1B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $798.0M | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 6 | total debt | us-gaap:LongTermDebt | $7.8B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 7 | book equity | us-gaap:StockholdersEquity | $54.0M | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.3B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 9 | total debt | us-gaap:LongTermDebt | $7.0B | 2024-12-31 | 2025-02-13 | 10-K | 25-000008 |
| 10 | book equity | us-gaap:StockholdersEquity | $212.0M | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.1B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 12 | net income | us-gaap:NetIncomeLoss | $2.1B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.2B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 14 | assets | us-gaap:Assets | $16.0B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $20.4B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 16 | gross profit | us-gaap:GrossProfit | $12.2B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $20.1B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 18 | gross profit | us-gaap:GrossProfit | $11.3B | 2023-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $19.5B | 2023-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 20 | gross profit | us-gaap:GrossProfit | $10.2B | 2022-12-31 | 2025-02-13 | 10-K | 25-000008 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $18.0B | 2022-12-31 | 2025-02-13 | 10-K | 25-000008 |
| 22 | gross profit | us-gaap:GrossProfit | $10.4B | 2021-12-31 | 2024-02-15 | 10-K | 24-000003 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $17.4B | 2021-12-31 | 2024-02-15 | 10-K | 24-000003 |
| 24 | current assets | us-gaap:AssetsCurrent | $5.7B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $6.9B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $26.6B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 27 | liabilities | us-gaap:Liabilities | $16.0B | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $630.0M | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $564.0M | 2025-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.1B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $561.0M | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $3.7B | 2023-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $705.0M | 2023-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $2.6B | 2022-12-31 | 2025-02-13 | 10-K | 25-000008 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $696.0M | 2022-12-31 | 2023-02-16 | 10-K | 23-000007 |
| 36 | current assets | us-gaap:AssetsCurrent | $5.3B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 37 | current liabilities | us-gaap:LiabilitiesCurrent | $5.8B | 2024-12-31 | 2026-02-23 | 10-K | 26-000006 |
| 38 | assets | us-gaap:Assets | $16.4B | 2023-12-31 | 2025-02-13 | 10-K | 25-000008 |
| 39 | assets | us-gaap:Assets | $15.7B | 2022-12-31 | 2024-02-15 | 10-K | 24-000003 |
| 40 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 801,548,028 | 2026-01-31 | 2026-02-23 | 10-K | 26-000006 |
| 41 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 811,536,437 | 2025-01-31 | 2025-02-13 | 10-K | 25-000008 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.